Fiduciary Trust Co. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,359 shares of the company’s stock after selling 50 shares during the period. Fiduciary Trust Co.’s holdings in Eli Lilly and were worth $852,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Heritage Trust Co purchased a new stake in Eli Lilly and during the 1st quarter worth $135,000. Point72 Asia Hong Kong Ltd boosted its position in Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares during the period. Shine Investment Advisory Services Inc. purchased a new stake in Eli Lilly and during the 2nd quarter worth $148,000. Cornerstone Advisors Inc. boosted its position in Eli Lilly and by 18.4% during the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after purchasing an additional 313 shares during the period. Finally, Penserra Capital Management LLC boosted its position in Eli Lilly and by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after purchasing an additional 176 shares during the period. 75.66% of the stock is owned by hedge funds and other institutional investors.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $82.53, for a total value of $15,680,700.00. Following the sale, the insider now directly owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 770,000 shares of company stock worth $64,669,850 over the last 90 days. Company insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Company (NYSE:LLY) opened at 82.65 on Tuesday. The stock has a 50 day moving average of $84.90 and a 200-day moving average of $82.19. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $89.09. The firm has a market cap of $87.20 billion, a price-to-earnings ratio of 35.76 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.72%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the business posted $0.88 EPS. Equities research analysts expect that Eli Lilly and Company will post $4.21 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a $0.52 dividend. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.52%. Eli Lilly and’s dividend payout ratio is 98.58%.
A number of analysts recently weighed in on the stock. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Leerink Swann upped their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their price target for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $89.76.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.